Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination.
At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive combined reduced-antigen-content diphtheria-tetanus and acellular pertussis vaccine (dTpa) versus tetanus-diphtheria (Td)+monovalent acellular pertussis (pa) were seroprotected against diphtheria (> or =0.016IU/mL Vero cell assay) and tetanus (> or =0.1IU/mL ELISA assay) in 94.4% and 96.2%, respectively (dTpa), compared with 93.7% and 90.6% (Td+pa). Anti-FHA, anti-PT and anti-PRN antibodies (> or =5EL.U/mL) were maintained in 100%, 89.5% and 95.0% of dTpa versus 100%, 85.5% and 90.6% of pa vaccine recipients. At 5 years post boosting, antibody levels to diphtheria and tetanus are similar amongst adults receiving a dTpa or dT, and pertussis antibodies remain above pre-booster levels in at least 85%.
McIntyre
Peter B
PB
National Centre for Immunisation Research and Surveillance, University of Sydney and The Children's Hospital at Westmead, Australia. peterm@chw.edu.au
Burgess
Margaret A
MA
Egan
Annemarie
A
Schuerman
Lode
L
Hoet
Bernard
B
D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000276:immunology*; D005260:Female; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009500:Neutralization Tests
D000907:Antibodies, Bacterial; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines